CellaVision AB (publ)
CLVSF · OTC
Market closed$14.00$0.00 (0.00%)After hours $14.00 · 0.00%
Key statistics
Previous close$14.00
Open$15.00
Day high$15.00
Day low$13.49
52-week high$19.28
52-week low$13.49
Market cap333.92M
Volume400.00
Average volume34.00
P/E ratio23.39
Forward P/E—
EPS0.60
Dividend yield+1.87%
Market context
Why it moved
CLVSF traded flat despite reporting its Q2 FY2026 earnings with net sales of SEK 200 million, up 4.5% year-over-year, as the in-line results met market expectations and provided little catalyst for a directional price move.
What is happening
Recent company-specific developments and publisher coverage.
Investing.com UK · July 17, 2026Earnings call transcript: CellaVision Q2 2026 sales rise as Americas hit recordwww.marketscreener.com · July 17, 2026CellaVision : Sales recovery with all-time high in AmericasBitget · July 17, 2026CellaVision Q2 FY26 profit before tax falls 14.58% to SEK 41 million; net sales rise 4.5% to SEK 200 millionwww.marketscreener.com · July 17, 2026Cellavision's EBITDA tops expectationswww.marketscreener.com · June 15, 2026Di sees potential for share price to double in CellaVision: issues buy recommendation (Stock of the Week)Simply Wall Street · February 9, 2026CellaVision Founder & Director Acquires 6.1% More Stock Mt Newswire · June 8, 2026Sweden's CellaVision Appoints New CEO Mt Newswire · December 8, 2025CellaVision's Bone Marrow Aspirate Software Secures In Vitro Diagnostic Regulation Class C Classification